Uveitis Associated with Juvenile Idiopathic Arthritis

Key points about this disease

• Juvenile idiopathic arthritis (JIA) is a chronic arthritis that develops in children under 16 years of age, and uveitis is the most important ocular complication.
• It is often asymptomatic in the early stages and is described as “white uveitis.”
• It accounts for 41–47% of all pediatric uveitis cases, and delayed diagnosis can lead to significant visual impairment. ¹⁾
• The incidence is highest in oligoarticular JIA (approximately 20%), with higher risk in patients who are ANA-positive, have young onset, and have a short disease duration. ³⁾
• The SYCAMORE trial (Ramanan 2017) demonstrated that combination therapy with adalimumab and methotrexate reduced treatment failure rates to 27% vs. 60%. ⁶⁾
• Screening enables early diagnosis, and with the introduction of monoclonal TNF inhibitors, visual prognosis has improved. ²⁾
• Ocular complications (band keratopathy, posterior synechiae, cataract, glaucoma) may develop in over 67% of cases, and appropriate treatment and regular follow-up are key to preserving vision.

1. What is uveitis associated with juvenile idiopathic arthritis?

Juvenile idiopathic arthritis (JIA) is a general term for chronic arthritis of unknown cause that develops in children under 16 years of age. It was formerly called juvenile rheumatoid arthritis. According to the ILAR criteria of the International League of Associations for Rheumatology, JIA is classified into seven subtypes: systemic, oligoarticular, RF-negative polyarticular, RF-positive polyarticular, psoriatic arthritis, enthesitis-related arthritis, and undifferentiated arthritis. Among these, the four subtypes—systemic, oligoarticular, RF-negative polyarticular, and RF-positive polyarticular—correspond to the former juvenile rheumatoid arthritis (JRA) and account for 94% of JIA cases.

Chronic uveitis is the most important ocular complication of JIA and is the most common cause of uveitis in children. It accounts for 41–47% of all pediatric uveitis cases. ¹⁾ Uveitis usually appears after the onset of arthritis, but in 3–7% of cases, it precedes arthritis. The median time to onset is 5.5 months, and it often develops within 5–7 years after arthritis onset; in particular, 82–90% of cases occur within the first 4 years. ³⁾

The rate of uveitis varies greatly depending on the JIA subtype.

JIA subtype	Uveitis rate	Risk
Persistent oligoarthritis	41–46%	High
RF-negative polyarthritis	5–23%	Moderate to high
Psoriatic arthritis	10–36%	Moderate
Enthesitis-related arthritis	7–25%	Moderate
Systemic arthritis	0%	Low

³⁾

It is observed in about 20% of oligoarticular type and about 5% of polyarticular type, and is not considered to occur in systemic type. In the Nordic cohort, uveitis was confirmed to complicate 10–22% of all JIA patients. ³⁾

Q Why is juvenile idiopathic arthritis-associated uveitis easily overlooked?

A

In the early stage, there are almost no subjective symptoms such as redness, pain, or photophobia, and it progresses quietly, often described as “white uveitis.” Especially in young children, subjective complaints are scarce and examination can be difficult. It is extremely difficult to detect without regular screening using a slit-lamp microscope.

2. Main symptoms and clinical findings

Ocular findings of juvenile idiopathic arthritis-associated uveitis. Showing posterior synechiae, keratic precipitates, and macular edema in the right eye.

Mahendradas P, et al. Reactivation of juvenile idiopathic arthritis associated uveitis with posterior segment manifestations following anti-SARS-CoV-2 vaccination. J Ophthalmic Inflamm Infect. 2022. Figure 1. PMCID: PMC9043884. License: CC BY.

Anterior segment photographs show irregular pupil due to posterior synechiae and keratic precipitates. Fundus photograph and OCT show opacity and cystoid macular edema in the right eye, indicating clinical findings of uveitis associated with juvenile idiopathic arthritis.

Subjective symptoms

The most prominent feature of JIA-associated uveitis is its initial asymptomatic nature.

• Asymptomatic (majority): Often lacks redness, eye pain, and photophobia. This leads to long-term diagnostic delay.
• Blurred vision and decreased visual acuity: Often first noticed when inflammation progresses and complications (cataract, macular edema) occur.
• Abnormal head posture and decreased concentration: May appear as symptoms specific to young children.
• Exception: In HLA-B27-positive boys, acute recurrent anterior uveitis may present with redness, eye pain, and photophobia.

Danger of being asymptomatic

Intraocular inflammation may persist for months to years without symptoms. During this time, irreversible complications such as band keratopathy and cataract may develop. Regular ophthalmologic examinations are essential even in the absence of symptoms.

Clinical Findings and Complications

97.8% of JIA-associated uveitis presents as anterior uveitis (iridocyclitis), typically bilateral and non-granulomatous. ²⁾ Many patients already have multiple complications at the time of ophthalmologic examination.

Band Keratopathy

Incidence: Approximately 32% of cases

Calcium deposition in the central cornea due to chronic inflammation, causing visual impairment. Treated with EDTA chelation or excimer laser.

Posterior Synechiae

Incidence: Approximately 28% of cases

Adhesion between the iris and lens. Often present at initial diagnosis and can cause pupillary block. Prophylaxis with mydriatics is important.

Complicated Cataract

Cumulative incidence: 0.05 per eye-year

Develops due to chronic inflammation and steroid use (approximately 22%). Cataract surgery is required under controlled active inflammation.

Secondary Glaucoma

Cumulative incidence: 0.03 per eye-year

Present in 15% of cases. More frequent in JIA-associated uveitis than in idiopathic uveitis. A major cause of poor visual prognosis. ²⁾

Other findings include inflammatory cells in the anterior vitreous, cystoid macular edema (3%), hypotony (9%), optic neuritis, and retinal vasculitis. Large cohort studies report that one-third of patients already have visual impairment at the first visit. Complications such as band keratopathy, posterior capsule opacification, and glaucoma develop in approximately 67% of cases cumulatively.

Q My child has been diagnosed with uveitis but doesn't seem to be in pain. Is it okay to leave it untreated?

A

Leaving it untreated can lead to vision loss. JIA-associated uveitis is a classic example of “painless uveitis” (white uveitis), where inflammation persists without symptoms, causing band keratopathy, cataracts, and glaucoma to progress. Even without symptoms, regular ophthalmology follow-up is the only way to protect vision.

3. Causes and Risk Factors

JIA-associated uveitis is a chronic inflammatory disease driven by autoimmune mechanisms, involving interactions between environmental factors and multiple genes. Overproduction of inflammatory cytokines (IL-1, IL-6, TNF-α) plays a central role in pathogenesis. In the joint synovium, granulation tissue called pannus forms, and a similar inflammatory cascade is continuously activated in the uvea.

Risk factors for developing uveitis (Nordic guideline 2023)³⁾:

• Young age at onset: Risk is particularly high when JIA onset is before age 6.
• Antinuclear antibody (ANA) positivity: Approximately 80% of uveitis cases are ANA-positive. The risk of developing uveitis increases up to 45%.
• Specific subtypes: Persistent oligoarthritis, RF-negative polyarthritis, and psoriatic arthritis.
• Short disease duration: 82–90% of uveitis cases occur within the first 4 years of JIA onset.
• HLA-DR5 and HLA-DR11 genetic predisposition.

Protective factors (significantly reduce the risk of developing uveitis)³⁾:

• Methotrexate (MTX): Hazard ratio HR 0.14–0.63.
• Monoclonal TNF inhibitors (adalimumab): HR 0.09 (alone or with MTX).
• Etanercept (TNF receptor inhibitor) has no protective effect: It does not work because its mechanism differs from that of monoclonal TNF antibodies.

For parents of children with JIA

Children diagnosed with juvenile idiopathic arthritis should have regular eye examinations even if they have no eye symptoms. The screening interval is individually determined based on risk factors (JIA subtype, antinuclear antibody, age at onset, and treatment medications). Continuing appropriate treatment with methotrexate or monoclonal TNF inhibitors also helps prevent uveitis.

4. Diagnosis and Examination Methods

The diagnosis of uveitis in JIA patients is often made during screening examinations. Detection at an asymptomatic stage directly leads to improved visual prognosis.

Ophthalmic Examination

• Slit-lamp microscopy: Evaluates anterior chamber inflammation, keratic precipitates, and posterior synechiae.
• Intraocular pressure measurement: Checks for high or low intraocular pressure.
• Visual acuity test: Performed using age-appropriate methods. In young children, examination under anesthesia may be necessary.
• Dilated fundus examination: Evaluates macular edema and optic nerve changes.
• OCT (Optical Coherence Tomography): Detects cystoid macular edema.

Serological Examination

• Antinuclear antibody (ANA): Positive (≥1:40) significantly increases the risk of uveitis. In oligoarticular type, the ANA positivity rate is high, and about 80% of cases with uveitis are positive.
• Rheumatoid factor (RF): Useful for risk stratification in RF-negative polyarticular type. Low positivity rate in oligoarticular type.
• HLA-B27: Tends to be positive in enthesitis-related arthritis and is associated with acute recurrent anterior uveitis.
• ESR and CRP: Elevated in systemic type, but often normal in oligoarticular type.

Screening Intervals (by Risk)

Risk stratification criteria combine JIA subtype, ANA positivity, age at onset, and disease duration. ^{3, 4)}

Risk level	Main criteria	Screening frequency
High risk	Oligoarthritis + ANA positive + onset ≤6 years + disease duration <4 years	Every 3 months
Moderate risk	Meets some of the above	Every 6 months
Low risk	Systemic type, RF-positive polyarthritis, ERA, onset >6 years	Every 12 months (for 2 years only)

• Screening frequency can be reduced during treatment with MTX or monoclonal TNF inhibitors. ³⁾
• After age 16, transition to self-monitoring, but the Nordic cohort reported 12 out of 434 cases with onset at age 23. ³⁾

Differential Diagnosis

Diseases that combine arthritis and uveitis include the following: ankylosing spondylitis, Reiter syndrome, psoriatic arthritis, sarcoidosis, inflammatory bowel disease, early-onset sarcoidosis (EOS), Blau syndrome, and TINU syndrome.

Q How often should I see an ophthalmologist?

A

It depends on the risk. For high risk (oligoarticular type, ANA positive, onset before age 6, disease duration less than 4 years), screening every 3 months is recommended. ^{3, 4)} For moderate risk, every 6 months; for low risk (systemic type, RF-positive polyarthritis, etc.), observation every 12 months for 2 years is a guideline. It is important to set the interval individually in collaboration with the pediatric rheumatologist and ophthalmologist.

5. Standard Treatment

Management of JIA-associated uveitis usually requires co-management by a pediatric rheumatologist and an ophthalmologist. Long-term control of inflammation is fundamental to preventing complications and protecting vision. Uveitis treatment guidelines recommend starting with local treatment and, for refractory cases, stepwise introduction of immunomodulatory therapy and biologic agents. ⁸⁾

Local Ocular Treatment (First Step)

• Betamethasone (Rinderon) 0.1% eye drops: 4–6 times daily (active phase). Used for acute control of inflammation.
• Dexamethasone eye drops: Equivalent effect.
• Mydriatic agents (Mydrin P eye drops): 1–3 times daily. Prevents posterior synechiae and manages pupil. When inflammation is quiet, observation with mydriatics alone may be done.

Caution with long-term use of topical steroids

Use less than 3 times daily is considered low risk for cataract development, but increased intraocular pressure and cataract are typical side effects of steroid eye drops. Regular monitoring of intraocular pressure and lens is essential during continued use.

Systemic Immunomodulatory Therapy

Drug	Dosage and Administration	Role
Methotrexate (MTX)	10–15 mg/m²/week (subcutaneous or oral)	First-line. Risk of uveitis onset HR 0.14–0.63
Adalimumab	Weight <30 kg: 20 mg/2 weeks, ≥30 kg: 40 mg/2 weeks (subcutaneous)	Second-line for MTX-refractory cases. Efficacy established in SYCAMORE trial
Infliximab	5 mg/kg at weeks 0, 2, 6, then every 8 weeks (intravenous)	Option for refractory cases
Tocilizumab (IL-6 inhibitor)	Approved for JIA arthritis in Japan	Evidence accumulating for uveitis
Etanercept	—	Ineffective for uveitis (due to TNF receptor inhibition)

Methotrexate (MTX) is the first-line immunomodulatory therapy for juvenile idiopathic arthritis-associated uveitis. ⁵⁾ It takes 4 to 12 weeks to take effect. In 27–48% of cases, MTX alone does not adequately control inflammation, and 20% experience side effects (vomiting, liver dysfunction). ²⁾

Adalimumab is positioned as a second-line option for MTX-refractory cases. The SYCAMORE trial (Ramanan 2017), a double-blind RCT, showed that the treatment failure rate was significantly reduced from 60% in the MTX-alone group to 27% in the MTX+adalimumab combination group (P<0.0001). ⁶⁾ It is approved for pediatric non-infectious uveitis. As a monoclonal TNF antibody, it has a protective effect on uveitis, unlike the TNF receptor inhibitor etanercept. ³⁾

The ADJUVITE trial (Quartier 2018) is a double-blind RCT of adalimumab for early chronic JIA-associated anterior uveitis. ⁷⁾ It is positioned as a study demonstrating the benefits of early introduction.

Before initiating TNF inhibitors, it is essential to perform tuberculosis and HBV screening and infection evaluation. Administration and management in collaboration with an ophthalmologist who is a member of the Ocular Inflammation Society is required. ⁹⁾

Treatment of Complications

• Band keratopathy: EDTA chelation, excimer laser ablation.
• Complicated cataract: Phacoemulsification + intraocular lens implantation (performed after confirming inflammation control). In young children, contact lens correction may be chosen without intraocular lens implantation. To prevent amblyopia, posterior capsulotomy and anterior vitrectomy are performed concurrently.
• Secondary glaucoma: Aqueous humor suppressant eye drops. For refractory cases, consider trabeculotomy, trabeculectomy, or Baerveldt implant.

Q Is it absolutely necessary to use adalimumab?

A

Not necessarily, but there is strong evidence from the SYCAMORE trial (Ramanan 2017) that the treatment failure rate was significantly reduced from 60% with MTX alone to 27% with combination therapy. ⁶⁾ The current standard approach is a stepwise strategy: first use MTX, and if adequate inflammation control is not achieved, consider adding adalimumab. To protect the child’s future vision, aggressive treatment is recommended when deemed necessary.

6. Pathophysiology and Detailed Mechanisms

The pathogenesis of JIA-associated uveitis is not fully understood, but immunological mechanisms are thought to be primarily involved.

Cellular immunity: CD4+ T cells (Th17 predominant) infiltrate uveal tissue and produce IL-17, IL-6, and TNF-α. Overproduction of inflammatory cytokines increases vascular endothelial permeability, sustaining edema and inflammatory cell infiltration in the iris and ciliary body. In the joint synovium, pannus formation leads to cartilage and bone destruction, and systemic symptoms such as fever, malaise, anemia, and growth impairment are also induced.

Association with autoantibodies: Antinuclear antibody (ANA) positivity is found in about 80% of patients with uveitis. Associations with HLA-DR5 (DRB1*1101) and HLA-DR11 have been reported in oligoarticular type. Autoreactive T-cell responses and activation of the classical complement pathway are also involved.

Dissociation from arthritis: Uveitis may persist independently even after arthritis symptoms subside. Because it continues through different inflammatory pathways, ongoing ophthalmologic monitoring is necessary even when arthritis is quiescent.

Main tissue changes resulting from chronic inflammation:

• Band keratopathy (32%): Calcium deposits in Bowman’s layer beneath the corneal epithelium.
• Posterior synechiae (28%): Fibrous adhesion between the iris and lens causes pupillary block.
• Secondary cataract (22%): Both inflammation and steroids cause lens opacification.
• Secondary glaucoma (15%): Aqueous outflow obstruction due to circumferential posterior synechiae, steroid-induced glaucoma.
• Cystoid macular edema (3%): A serious complication affecting visual prognosis.

---

7. Latest Research and Future Perspectives (Investigational Reports)

For patients: Please read carefully

The following content is currently under investigation or in clinical trials and is not standard treatment available at general hospitals. It is reference information for professionals regarding future medical developments.

Results of the SYCAMORE Trial

Ramanan et al. (2017) conducted a double-blind RCT comparing MTX alone vs. MTX + adalimumab, showing that the adalimumab group reduced treatment failure rates to 27% vs. 60% (P<0.0001). ⁶⁾ This trial provided the basis for approval of adalimumab for pediatric non-infectious uveitis. Long-term follow-up data are being accumulated with predefined discontinuation criteria.

Visual Prognosis in the Era of Biologics

In a retrospective study from the Bristol area by Cann et al. (2018), among 166 children with non-infectious uveitis, the use of biologics reached 35%, with an incidence of visual loss (logMAR > 0.3) of 0.05/eye-year and severe visual loss (logMAR ≥ 1.0) of 0.01/eye-year. ²⁾ This represents an improvement from 0.10/eye-year before the introduction of biologics, demonstrating the progress of treatment.

MIWGUC 2023 Revised Recommendations

The latest recommendations from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC) by Foeldvari et al. (2023) clearly recommend early introduction of adalimumab for MTX-refractory JIA-associated uveitis and advise against selecting etanercept for the treatment of uveitis. ¹⁰⁾

JAK Inhibitors and New Agents

The efficacy of JAK inhibitors such as ruxolitinib and tofacitinib for refractory JIA-associated uveitis has been reported in case reports and small series, but definitive evidence is not yet available at this time.

Challenges in the Transition to Adult Care

In the Nordic cohort, new-onset cases were observed even after the transition to adult care after age 16 (12 of 434 cases were new-onset at age 23), highlighting the challenge of seamless collaboration from childhood to adulthood. ³⁾ Since MTX and MMF are teratogenic, adalimumab is considered a relatively safe option for women of childbearing age when selecting medications.

---

8. References

1. Clarke SLN, Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Pediatr Rheumatol. 2016;14:27.
2. Cann M, Ramanan AV, Crawford A, et al. Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy. Pediatr Rheumatol Online J. 2018;16(1):51. doi:10.1186/s12969-018-0266-5. PMID:30081917; PMCID:PMC6080499.
3. Leinonen S. A Nordic screening guideline for juvenile idiopathic arthritis-related uveitis. Acta Ophthalmologica. 2023;101:465-468.
4. Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Care Res. 2019;71(6):703-716.
5. Heiligenhaus A, Michels H, Schumacher C, et al. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int. 2012;32(5):1121-1133.
6. Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis (SYCAMORE). N Engl J Med. 2017;376(17):1637-1646.
7. Quartier P, Baptiste A, Despert V, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2018;77(7):1003-1011.
8. 日本眼炎症学会. ぶどう膜炎診療ガイドライン. 日眼会誌. 2019;123(6):635-696.
9. 日本眼炎症学会 TNF阻害薬使用検討委員会. 非感染性ぶどう膜炎に対するTNF阻害薬使用指針および安全対策マニュアル（改訂第2版、2019年版）. 日眼会誌. 2019.
10. Foeldvari I, Maccora I, Petrushkin H, et al. New and updated recommendations for the treatment of JIA associated uveitis (MIWGUC). Arthritis Care Res. 2023;75(5):975-982.